Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$1.79 USD
+0.14 (8.48%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.75 -0.04 (-2.23%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Sensei Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 66 | 107 | 148 | 17 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 3 | 0 |
Total Current Assets | 67 | 109 | 149 | 20 | 1 |
Net Property & Equipment | 1 | 2 | 5 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 74 | 118 | 153 | 21 | 1 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 4 | 2 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 16 |
Current Portion Capital Leases | 1 | 1 | 1 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 1 | 1 |
Total Current Liabilities | 6 | 9 | 5 | 5 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | 1 | 2 | 2 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 72 | 48 |
Total Liabilities | 9 | 15 | 7 | 78 | 70 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 297 | 302 | 296 | 56 | 24 |
Retained Earnings | -232 | -198 | -149 | -112 | -92 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 65 | 103 | 147 | -56 | -69 |
Total Liabilities & Shareholder's Equity | 74 | 118 | 153 | 21 | 1 |
Total Common Equity | 65 | 103 | 147 | -56 | -69 |
Shares Outstanding | 25.00 | 30.70 | 30.60 | NA | NA |
Book Value Per Share | 2.60 | 3.37 | 4.79 | 0.00 | 0.00 |
Fiscal Year End for Sensei Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 66 | 72 | 79 | 96 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 2 | 2 | 3 |
Total Current Assets | NA | 67 | 74 | 81 | 99 |
Net Property & Equipment | NA | 1 | 1 | 1 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 74 | 82 | 90 | 108 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 2 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 1 | 1 | 1 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 1 | 1 | 1 |
Total Current Liabilities | NA | 6 | 6 | 5 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 9 | 11 | 10 | 13 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 297 | 296 | 297 | 304 |
Retained Earnings | NA | -232 | -224 | -217 | -208 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 65 | 71 | 79 | 95 |
Total Liabilities & Shareholder's Equity | NA | 74 | 82 | 90 | 108 |
Total Common Equity | 0 | 65 | 71 | 79 | 95 |
Shares Outstanding | 25.00 | 25.00 | 26.50 | 26.50 | 30.90 |
Book Value Per Share | 0.00 | 2.60 | 2.68 | 2.99 | 3.07 |